Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial

Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC). Preclinical evidence suggests that the sequential administration of IRI and FU produces synergistic activity, although their clinical use has not been fully...

詳細記述

保存先:
書誌詳細
主要な著者: Barone, C, Landriscina, M, Quirino, M, Basso, M, Pozzo, C, Schinzari, G, Leonardo, G Di, D'Argento, E, Trigila, N, Cassano, A
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2007
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360198/
https://ncbi.nlm.nih.gov/pubmed/17164761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603496
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料